Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiation Oncology | 3 | 2023 | 555 | 1.110 |
Why?
|
| Commerce | 1 | 2022 | 592 | 0.570 |
Why?
|
| Internship and Residency | 3 | 2022 | 5787 | 0.560 |
Why?
|
| Breast Neoplasms, Male | 1 | 2017 | 210 | 0.510 |
Why?
|
| Choroid Neoplasms | 1 | 2016 | 175 | 0.500 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2015 | 358 | 0.480 |
Why?
|
| Curriculum | 4 | 2023 | 3604 | 0.460 |
Why?
|
| Carcinoma, Lobular | 1 | 2017 | 484 | 0.430 |
Why?
|
| Educational Measurement | 1 | 2019 | 1209 | 0.420 |
Why?
|
| Rectal Neoplasms | 2 | 2021 | 1203 | 0.390 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2017 | 1101 | 0.340 |
Why?
|
| Brachytherapy | 1 | 2016 | 1246 | 0.310 |
Why?
|
| SEER Program | 3 | 2017 | 1508 | 0.290 |
Why?
|
| Lymph Nodes | 1 | 2017 | 3469 | 0.260 |
Why?
|
| Buprenorphine | 2 | 2023 | 640 | 0.260 |
Why?
|
| Radiology | 1 | 2019 | 2099 | 0.260 |
Why?
|
| Smoking | 1 | 2022 | 8986 | 0.250 |
Why?
|
| Opioid-Related Disorders | 3 | 2023 | 2065 | 0.240 |
Why?
|
| Clinical Competence | 1 | 2019 | 4687 | 0.230 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 1770 | 0.190 |
Why?
|
| Adenosine Diphosphate | 1 | 2022 | 425 | 0.190 |
Why?
|
| Naloxone | 1 | 2023 | 367 | 0.190 |
Why?
|
| Education, Medical, Graduate | 2 | 2022 | 2291 | 0.170 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 5257 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 2726 | 0.150 |
Why?
|
| Harm Reduction | 3 | 2023 | 129 | 0.150 |
Why?
|
| Clinical Clerkship | 1 | 2023 | 532 | 0.150 |
Why?
|
| Melanoma | 1 | 2016 | 5475 | 0.150 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2017 | 62 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6535 | 0.130 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2023 | 1007 | 0.120 |
Why?
|
| Burnout, Professional | 1 | 2023 | 694 | 0.120 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 11007 | 0.110 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 1076 | 0.110 |
Why?
|
| Philadelphia | 2 | 2023 | 263 | 0.110 |
Why?
|
| Receptors, Progesterone | 1 | 2017 | 1097 | 0.100 |
Why?
|
| Preoperative Care | 1 | 2021 | 2246 | 0.100 |
Why?
|
| Postoperative Period | 1 | 2017 | 1841 | 0.100 |
Why?
|
| Survival Rate | 2 | 2016 | 12781 | 0.100 |
Why?
|
| Remission Induction | 1 | 2016 | 2389 | 0.090 |
Why?
|
| Students, Medical | 1 | 2023 | 1862 | 0.090 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 3674 | 0.090 |
Why?
|
| Internet | 1 | 2022 | 3063 | 0.090 |
Why?
|
| Receptors, Estrogen | 1 | 2017 | 2186 | 0.080 |
Why?
|
| Humans | 16 | 2023 | 744220 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2017 | 6367 | 0.080 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 4259 | 0.070 |
Why?
|
| Aged | 6 | 2023 | 163253 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 8628 | 0.060 |
Why?
|
| Male | 9 | 2023 | 350027 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 4841 | 0.060 |
Why?
|
| Adult | 5 | 2022 | 214035 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2017 | 10250 | 0.060 |
Why?
|
| United States | 3 | 2023 | 69867 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2021 | 77426 | 0.040 |
Why?
|
| Middle Aged | 4 | 2021 | 213367 | 0.040 |
Why?
|
| Young Adult | 2 | 2016 | 56436 | 0.040 |
Why?
|
| Opiate Substitution Treatment | 1 | 2023 | 404 | 0.040 |
Why?
|
| Age Factors | 1 | 2016 | 18367 | 0.040 |
Why?
|
| Female | 6 | 2023 | 380197 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 6352 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 9230 | 0.040 |
Why?
|
| Informed Consent | 1 | 2022 | 995 | 0.030 |
Why?
|
| Educational Status | 1 | 2023 | 2539 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2021 | 950 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2023 | 2682 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 39045 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 57768 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2021 | 6461 | 0.020 |
Why?
|
| Medicaid | 1 | 2023 | 2736 | 0.020 |
Why?
|
| Health Personnel | 1 | 2023 | 3216 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 63119 | 0.020 |
Why?
|
| Communication | 1 | 2022 | 3749 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 1990 | 403 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 5138 | 0.020 |
Why?
|
| Medicare | 1 | 2023 | 6566 | 0.020 |
Why?
|
| Hospitalization | 1 | 2023 | 10262 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 15538 | 0.010 |
Why?
|
| Pandemics | 1 | 2023 | 8387 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2021 | 15294 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 40559 | 0.010 |
Why?
|
| Leukemia L1210 | 1 | 1990 | 45 | 0.010 |
Why?
|
| Pentanones | 1 | 1990 | 12 | 0.010 |
Why?
|
| Cobalt | 1 | 1990 | 158 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1990 | 348 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1990 | 1827 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1990 | 13668 | 0.000 |
Why?
|
| Organometallic Compounds | 1 | 1990 | 665 | 0.000 |
Why?
|
| Neoplasm Transplantation | 1 | 1990 | 2085 | 0.000 |
Why?
|
| Cell Survival | 1 | 1990 | 5881 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1990 | 4033 | 0.000 |
Why?
|
| Mice | 1 | 1990 | 81178 | 0.000 |
Why?
|
| Animals | 1 | 1990 | 168788 | 0.000 |
Why?
|
Concepts
(93)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(7)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_